Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis [PDF]
Vojnosanitetski Pregled, 2020 Backgroun/Aim. Although majority of guidelines recommend triazoles (voriconazole, posaconazole, itraconazole and isavuconazole) as first-line therapeutic option for treatment of invasive aspergillosis, echinocandins (caspofungin, micafungin and ...
Uzelac Sanja M. +4 more
doaj +3 more sources
Review on Current Status of Echinocandins Use [PDF]
Antibiotics, 2020 Fungal infections are rising all over the world every year. There are only five medical compound classes for treatment: triazoles, echinocandins, polyenes, flucytosine and allylamine.
Martyna Mroczyńska +1 more
doaj +2 more sources
Echinocandins have an alternative mode of action on biomimetic membranes that is not directly related to the functioning of (1,3) beta-glucan synthase [PDF]
Cell Death DiscoveryEchinocandins are the preferred agents for treating invasive candidiasis; however, rising resistance in Candida species poses a significant challenge for patient care.
Anna I. Malykhina +5 more
doaj +2 more sources
The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2020 Invasive fungal infections continue to show steady growth among various patient populations, accompanied by high rates of both morbidity and attributive mortality.
Veselov A.V.
doaj +3 more sources
Evaluation of Fluconazole versus Echinocandins for Treatment of Candidemia Caused by Susceptible Common Candida Species: A Propensity Score Matching Analysis [PDF]
Journal of Fungi, 2023 This study aimed to evaluate the effectiveness of fluconazole and echinocandins in the treatment of candidemia caused by both fluconazole- and echinocandin-susceptible common Candida species. A retrospective study which enrolled adult candidemia patients
Jong Hun Kim, Jin Woong Suh, Min Ja Kim
doaj +2 more sources
Yeast infections in sterile body fluids: species distribution, antifungal susceptibility, and cross-cutting risk factors for fungemia, sepsis, and mortality (2019–2023) [PDF]
Frontiers in MicrobiologyBackgroundYeast infections from sterile body fluids are increasingly encountered in tertiary care, yet contemporary links between species ecology, antifungal susceptibility, and patient outcomes remain underdefined.MethodsWe conducted a retrospective ...
Jiaxing Liu +7 more
doaj +2 more sources
Frontiers in Oncology, 2021 Invasive Candida glabrata infections are not common complications after radical cystoprostatectomy. Furthermore, resistance to echinocandins arising during the course of a patient’s treatment is rarely recognised.
Maria Szymankiewicz +6 more
doaj +1 more source
Journal of Fungi, 2021 This study was designed to analyze the interaction of 21 antifungal combinations consisting of seven major antifungal agents against 11 echinocandin- susceptible and six-resistant C. glabrata isolates. The combinations were divided into five major groups
Hazim O. Khalifa +3 more
doaj +1 more source
BMC Infectious Diseases, 2017 Background Cost-effectiveness studies of echinocandins for the treatment of invasive candidiasis, including candidemia, are rare in Asia. No study has determined whether echinocandins are cost-effective for both Candida albicans and non-albicans Candida ...
Huang-Tz Ou +3 more
doaj +1 more source
mSphere, 2022 There is an urgent need for new antifungals to treat cryptococcal meningoencephalitis, a leading cause of mortality in people living with HIV/AIDS. An important aspect of antifungal drug development is the validation of targets to determine whether they ...
Sarah R. Beattie +4 more
doaj +1 more source